Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 67 In phase 3a trials semaglutide shows best in-class weight lowering potential across treatment cascade Comparison of weight lowering effect in SUSTAIN 1, 2, 3, 4 and 5 trials Sema 1 mg Sema 0.5 mg SUSTAIN 1 92kg Placebo SUSTAIN 2 89kg Baseline Sitagliptin 100 mg SUSTAIN 3 96kg Exenatide QW SUSTAIN 4 93kg Insulin glargine QD SUSTAIN 5 92kg Change in weight (kg) 1.0 0.0 -1.0 -2.0 -3.0 -3.7 -4.0 -4.5 -5.0 -6.0 -7.0 -1.0 -6.1 -4.3 -1.9 -1.9 * -5.2 -5.6 *p < 0.001; QD: once daily; QW: once weekly; sema: semaglutide Source: Novo Nordisk on file (NN9535-3623, NN9535-3624, NN9535-3625, NN9535-3626, NN9535-3627) changing diabetes® * -3.5 1.2 -6.4 -3.7 * -1.4 novo nordisk

View entire presentation